Bisphosphonates and bone metastases: current status and future directions

Area of Science:

• Oncology
• Bone Metabolism
• Cancer Therapy

Background:

• Bone metastases are a common complication in advanced cancer, leading to significant skeletal-related morbidities.
• Effective treatment of bone metastases remains a critical challenge in cancer care.
• Skeletal-related events (SREs) negatively impact patient quality of life and prognosis.

Purpose of the Study:

• To evaluate the efficacy and safety of bisphosphonates in managing bone metastases from advanced cancer.
• To highlight the role of bisphosphonates in preventing skeletal-related complications.
• To emphasize the importance of evidence-based use of bisphosphonates in clinical practice.

Main Methods:

• Systematic review and meta-analysis of clinical trials investigating bisphosphonate therapy for bone metastases.
• Assessment of outcomes including fracture incidence, need for radiotherapy, hypercalcemia, and bone microstructure preservation.
• Evaluation of bisphosphonate safety profiles and incidence of serious side effects.

Main Results:

• Bisphosphonates significantly reduced the odds of fractures, the need for radiotherapy, and the incidence of hypercalcemia.
• Proven ability of bisphosphonates in preserving the 3D bone microstructure, crucial for bone stability.
• Bisphosphonates demonstrated a favorable safety profile with a low incidence of serious adverse events.

Conclusions:

• Bisphosphonates are the established standard of care for treating malignant bone disease due to their efficacy and safety.
• The benefits of bisphosphonate treatment are dose- and duration-dependent, suggesting prolonged use is advantageous.
• Continued bisphosphonate therapy should be guided by clinical relevance and supported by robust evidence to ensure optimal resource allocation.